261953-36-0

Basic information

• Product Name: 6-IODO (1H)INDAZOLE
• Synonyms: 6-IODO (1H)INDAZOLE;6-IODOINDAZOLE;1H-Indazole, 6-iodo-;6-iodo-1h1indazole;261953-36-0
• CAS NO: 261953-36-0
• Molecular Formula: C₇H₅IN₂
• Molecular Weight: 244.03247
• EINECS: 1592732-453-0
• Product Categories: pharmacetical
• Mol File: 261953-36-0.mol

Chemical Properties

• Melting Point: 207.0 to 211.0 °C
• Boiling Point: 358.2°Cat760mmHg
• Flash Point: 170.4°C
• Appearance: Clear colorless to light yellow/Liquid
• Density: 2.082g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.788
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.96±0.40(Predicted)
• CAS DataBase Reference: 6-IODO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-IODO (1H)INDAZOLE(261953-36-0)
• EPA Substance Registry System: 6-IODO (1H)INDAZOLE(261953-36-0)

Safety Data

• Hazardous Substances Data: 261953-36-0(Hazardous Substances Data)

Usage

Physical Form

Light yellow to Brown powder to crystal

Uses

6-Iodo-1H-indazole is an intermediate used to synthesize inhibitors of Chk1.

InChI:InChI=1/C7H5IN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)

Upstream product

• 6967-12-0 6-amino-1H-indazole 
• 7597-18-4 6-nitroindazole 
• 83863-33-6 5-iodo-o-toluidine 
• 850363-52-9 1-acetyl-6-iodo-1H-indazole 
• 79762-54-2 6-bromo-1H-indazole 

Downstream Products

• 319472-78-1 3,6-diiodoindazole 
• 944835-85-2 2-{(1H-indazol-6-yl)thio}-N-methylbenzamide 
• 281203-98-3 6-(thiophen-3-yl)-1H-indazole 
• 319472-53-2 6-iodo-1-(2,4,6-trimethyl-benzenesulfonyl)-1H-indazole 
• 947311-93-5 4-(1H-indazol-6-ylethynyl)-2-nitrophenylamine 
• 1093847-81-4 6-(trimethylsilyl)ethynyl-1H-indazole 
• 321745-26-0 6-iodo-1-isopropyl-1H-indazole 
• 929192-91-6 6-iodo-2-(2-pyrrolidin-1-ylethyl)-2H-indazole 
• 929192-90-5 6-iodo-1-(2-pyrrolidin-1-ylethyl)-1H-indazole 
• 1254714-64-1 C₁₄H₁₁IN₂ 
• 1394117-32-8 4-[1-(2-amino-5-chloropyrimidin-4-yl)-1H-indazol-6-yl]-2-(1,3-thiazol-2-yl)but-3-yn-2-ol 
• 1394119-36-8 5-chloro-4-(6-iodo-1H-indazol-1-yl)pyrimidin-2-amine 
• 1394120-84-3 6-(6-iodoindazol-1-yl)pyrimidin-4-amine 
• 1394120-83-2 6-(6-iodoindazol-1-yl)-N-(2-methoxypyridin-3-yl)pyrimidin-4-amine 

Relevant articles and documents

A 6 - iodo - 1H - indazole synthesis method

The invention discloses a 6 - iodo - 1 H - indazole synthesis method, the synthetic route shown in the following chart: The formula V compounds as the starting material, in under the action of the iodinating agent and catalyst, replacing V compound after the nucleus of the atom, to get the object product, disclosed by the present invention the above-mentioned process route, effectively overcomes the design defects of existing synthetic route, in order to green, few synthesis steps, high yield, production cycle is short and there is little impurity content of the process route, for the preparation of 6 - iodo - 1 H - indazole compound.

ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF

The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.

PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

Bicyclic aromatic substituted pyridone derivative

Disclosed is a compound represented by the formula (I): Wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1, X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, —O— or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE

Disclosed is a compound represented by the formula (I): wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1, X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, -O- or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methlene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

4-Substituted indazoles as new inhibitors of neuronal nitric oxide synthase

A series of halo-1-H-indazoles has been synthesized and evaluated for its inhibitory activity on neuronal nitric oxide synthase. Introduction of bromine at the C4 position of the indazole ring system provided a compound almost as potent as the reference compound, that is, 7-nitroindazole (7-NI). The importance of position 4 is further demonstrated by the synthesis and pharmacological evaluation of the 4-nitroindazole which was also a potent inhibitor of NOS activity. These compounds also exhibited in vivo NOS inhibitory activity, as attested by potent antinociceptive effects following systemic administration.

NOVEL INDAZOLE DERIVATIVE

An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.

Heterocyclic compounds for the treatment of migraine

Described herein are compounds useful in the treatment of migraine, which have the general formula: wherein: W is a CH group or a N atom; Z is N or C—R4; B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N; A is a group of Formula II, III or IV, such that group A contains at least 1 N atom; NR7 is either —NH— or —N═;is a single or double bond; X is a N atom, a CH group or a C(OH) group whenis a single bond; or, whenis a double bond, a C atom; Y is an NH, N-alkyl, N-benzyl or CH2group; U and V each represent a N atom or a CH group, with the proviso that both cannot be N; a and b are, independently, 0 or 1; c is an integer from 0 to 3; d is an integer from 1 to 3; e is an integer from 1 to 2; f is an integer from 0 to 3; g is an integer from 3 to 6 and h is an integer from 2 to 3; such that the sum of c and d is at least 2 and the sum of e and f is at least 2; and salts and solvates thereof.

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.